ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 754

Dynamic Distribution and Phenotype Shift from M1 to M2 of Macrophages in Vascular Lesions of Naïve and Treated Patients with Takayasu Arteritis

Xiufang Kong1, Ming Xu 2, Xiaomeng Cui 2, Lingying Ma 2, Huiyong Chen 3, Lili Ma 2 and Lindi Jiang 2, 1University of Michigan & Fudan University, Ann Arbor, MI, 2Zhongshan Hospital, Fudan University, Shanghai, China (People's Republic), 3Department of Rheumatology, Zhongshan Hospital, Fudan University, Shanghai, P. R. China, Shanghai

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: macrophages and phenotypes, Takayasu.s arteritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster I: Takayasu's Arteritis & Polymyalgia Rheumatica

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Takayasu arteritis (TA) is a chronic inflammatory disease characterized by arterial vascular fibrosis. Type I (M1) and type II (M2) macrophages play very important roles in the development of TA, and monocyte chemotactic protein-1 (MCP-1) has also been implicated in TA. However, the roles and interactions of these three factors with each other and with the current therapeutic agents for TA are unclear. Therefore, in the current study, we investigated the M1 and M2 profile in the vascular tissue of TA patients and detected the concentration of monocyte chemotactic protein-1 (MCP-1) in vascular tissue and peripheral blood before and after treatment.

Methods: This study included 8 untreated TA patients, 7 treated patients and 4 controls who provided vascular tissue specimens, as well as 38 treatment-naïve patients and 28 healthy controls who provided their serum samples before and after treatment (only 19 TA samples were obtained after treatment). The treatment strategy was prednisone combined with immunosuppressants. Immunohistochemical staining for M1 and M2 markers and MCP-1 was performed in the vascular tissue samples. The serum level of MCP-1 was detected by ELISA. Disease activity was evaluated by the Kerr activity score.

Results: M1 macrophages were more prominent in the acute (pro-inflammatory) stage of TA and in naïve patients, while M2 macrophages were more prominent in the chronic (pro-fibrotic) stage and in treated patients. This pattern was also observed in MCP-1 expression. Macrophages and MCP-1 showed increased levels in vascular tissue (mainly in the adventitia), along with an increase in peripheral MCP-1, in the treatment-naïve patients. In contrast, in the patients who had received 6 months of treatment, both the macrophage and MCP-1 (vascular adventitia and peripheral) levels were decreased. In the vascular media from treated patients, an increase in MCP-1 levels and M2 infiltration was observed. Furthermore, peripheral MCP-1 was correlated Kerr activity score (Rho = 0.50, P = 0.002) and peripheral IL-6 levels (Ro = 0.55, P < 0.001).

Conclusion: In the vascular wall, M1 and M2 distribution is dynamic and is closely associated with MCP-1 expression, which is increased in the serum and vascular tissue of TA patients. The current treatment strategies do not target M2 infiltration, as a result of which fibrosis is aggravated. Thus, more efficacious treatment strategies that target both M1 and M2 should be used. Further, the serum level of MCP-1 may prove to be a useful indicator of disease stage and treatment efficacy in the future.

 


Figure 2 5-15

Figure 1. Distribution and phenotype of macrophages in untreated vascular tissue -inflammatory stage-


Figure 3 5-16

Figure 2. Distribution and phenotype of macrophages in treated vascular tissue -fibrotic stage-


Figure 4 5-15

Figure 3. MCP-1 expression in normal aorta, untreated TA aorta and treated TA artery


Disclosure: X. Kong, None; M. Xu, None; X. Cui, None; L. Ma, None; H. Chen, None; L. Ma, None; L. Jiang, None.

To cite this abstract in AMA style:

Kong X, Xu M, Cui X, Ma L, Chen H, Ma L, Jiang L. Dynamic Distribution and Phenotype Shift from M1 to M2 of Macrophages in Vascular Lesions of Naïve and Treated Patients with Takayasu Arteritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/dynamic-distribution-and-phenotype-shift-from-m1-to-m2-of-macrophages-in-vascular-lesions-of-naive-and-treated-patients-with-takayasu-arteritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/dynamic-distribution-and-phenotype-shift-from-m1-to-m2-of-macrophages-in-vascular-lesions-of-naive-and-treated-patients-with-takayasu-arteritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology